ATE435872T1 - Anti-interleukin-1 rezeptor antikörper und deren verwendung - Google Patents

Anti-interleukin-1 rezeptor antikörper und deren verwendung

Info

Publication number
ATE435872T1
ATE435872T1 AT04764984T AT04764984T ATE435872T1 AT E435872 T1 ATE435872 T1 AT E435872T1 AT 04764984 T AT04764984 T AT 04764984T AT 04764984 T AT04764984 T AT 04764984T AT E435872 T1 ATE435872 T1 AT E435872T1
Authority
AT
Austria
Prior art keywords
interleukin
receptor antibodies
antibodies
receptor
Prior art date
Application number
AT04764984T
Other languages
English (en)
Inventor
Ilse Bartke
Francis Carr
Anthony Chizzonite
Elsie Eugui
Georg Fertig
Anita Hamilton
Martin Lanzendoerfer
Petra Rueger
Ralf Schumacher
Theresa Truitt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42778436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE435872(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE435872T1 publication Critical patent/ATE435872T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04764984T 2003-09-10 2004-09-09 Anti-interleukin-1 rezeptor antikörper und deren verwendung ATE435872T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50168103P 2003-09-10 2003-09-10
EP03029659 2003-12-23
PCT/EP2004/010047 WO2005023872A1 (en) 2003-09-10 2004-09-09 Antibodies against interleukin-1 receptor and uses thereof

Publications (1)

Publication Number Publication Date
ATE435872T1 true ATE435872T1 (de) 2009-07-15

Family

ID=42778436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764984T ATE435872T1 (de) 2003-09-10 2004-09-09 Anti-interleukin-1 rezeptor antikörper und deren verwendung

Country Status (13)

Country Link
US (2) US20050118169A1 (de)
EP (1) EP1664121B1 (de)
JP (1) JP2007527230A (de)
AR (1) AR045614A1 (de)
AT (1) ATE435872T1 (de)
AU (1) AU2004270390A1 (de)
BR (1) BRPI0414259A (de)
CA (1) CA2538319A1 (de)
MX (1) MXPA06002728A (de)
NZ (1) NZ545761A (de)
RU (1) RU2369617C2 (de)
TW (1) TWI295672B (de)
WO (1) WO2005023872A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099747A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR20080077237A (ko) 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
CN101460522B (zh) * 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
CA2693443C (en) 2007-07-17 2018-02-13 F. Hoffmann-La Roche Ag Variable tangential flow filtration
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010080463A1 (en) * 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
CN105624118B (zh) 2009-10-19 2019-08-13 弗·哈夫曼-拉罗切有限公司 非交叉反应性抗IgG抗体
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
KR101584416B1 (ko) 2010-10-05 2016-01-13 에프. 호프만-라 로슈 아게 인간 tweak에 대한 항체 및 그의 용도
CN103492416A (zh) 2011-04-15 2014-01-01 默克专利股份公司 用于癌症中使用的抗il-1r1抑制剂
US9365881B2 (en) 2011-10-05 2016-06-14 Hoffmann-La Roche Inc. Process for antibody G1 glycoform production
AR088579A1 (es) 2011-10-31 2014-06-18 Genentech Inc Formulaciones de anticuerpos
SG11201405830VA (en) * 2012-03-27 2014-10-30 Genentech Inc Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
JP6594860B2 (ja) 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
EP3017057B1 (de) 2013-07-05 2019-10-02 F.Hoffmann-La Roche Ag Verfahren zur mono- und bi-sialylierung von glykoproteinen unter verwendung von n-terminal verkürzten mutanten der beta-galaktosid alpha-2,6-sialyltransferase
EP3551034A1 (de) 2016-12-07 2019-10-16 Progenity, Inc. Verfahren, vorrichtungen und systeme zur detektion des magen-darm-trakts
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
PT1074268E (pt) * 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L

Also Published As

Publication number Publication date
TW200513261A (en) 2005-04-16
MXPA06002728A (es) 2006-06-06
US20050118169A1 (en) 2005-06-02
NZ545761A (en) 2008-10-31
TWI295672B (en) 2008-04-11
BRPI0414259A (pt) 2006-11-07
US20090191187A1 (en) 2009-07-30
EP1664121B1 (de) 2009-07-08
WO2005023872A1 (en) 2005-03-17
RU2369617C2 (ru) 2009-10-10
AR045614A1 (es) 2005-11-02
AU2004270390A1 (en) 2005-03-17
CA2538319A1 (en) 2005-03-17
JP2007527230A (ja) 2007-09-27
RU2006111579A (ru) 2007-10-27
EP1664121A1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
ATE456581T1 (de) Antikörper gegen il21-rezeptor und deren verwendung
DE602004031988D1 (de) Antikörper gegen insulinartigen Wachstumsfaktor-I-Rezeptor und deren Verwendung
ATE446953T1 (de) P2x7-rezeptorantagonisten und deren verwendung
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
CY2016016I2 (el) Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
ATE470675T1 (de) Immunoglobulinvarianten und deren verwendungen
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE60324767D1 (de) Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
DK2662390T3 (da) Interferon alpha receptor 1-antistoffer og anvendelse heraf
DE60328087D1 (de) Aryl substituierte pyrimidine und deren verwendung
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE602004031607D1 (de) Propylenpolymerzusammensetzung und verwendung davon
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
DE602004028700D1 (de) Kosmetische Zusammensetzungen und deren Verwendung
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
FI20060188L (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE60328713D1 (de) Blockcopolymer-modifizierte bitumenpappen und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties